Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Sotac Pharmaceutical IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2015 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 105  to  111 per share
Profile
Min Investment ₹111
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Sotac Group is a well-known pharmaceutical producer in India that was founded in 2014 and specialises in producing a wide variety of pharmaceutical products. The company makes pharmaceutical medicines through loan licences or contract production agreements for various marketers. The majority of the company's business is conducted on a principle-to-principle basis with various marketers. On a loan licence and/or contract manufacturing basis, SOTAC provides services to over 162 corporate clients. The company is expanding and growing its scope of operations every year thanks to their extensive experience in the pharmaceutical industry.A lot of healthcare professionals will be able to purchase high-quality products from the business at reasonable prices. Read More

Basic Info

Face Value 10 per share

Price 105  to  111 per share

P/E (x) 15.2

Sales( Cr.) 97

PAT( Cr.) 9

EPS 7.3

Draft Prospectus

Exchange NSE-SME

Promoter

Company Promoters

Mr. Sharadkumar Dashrathbhai Patel Mr. Dineshkumar Babulal Gelot Mr. Vishalkumar Devrajbhai Patel Mr. Chetankumar Bachubhai Patel

Pre Issue Share Holding 100%

Post Issue Share Holding 72.85%

Listing Details:

Listing Price: 115

Listing Gain: 3.48%

Current Price: 111

Gain On Issue: 111 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Mar 29, 2023
Closing Date Apr 03, 2023
Allotment Apr 04, 2023
Refund Apr 05, 2023
Delivery of Shares Apr 05, 2023
Listing Date Apr 06, 2023

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 1200 133,200
Retail (Max) 1 1200 133,200
S-HNI (Min) 2 2400 266,400
S-HNI (Max) 7 8400 932,400
B-HNI (Min) 8 9600 1,065,600

Objective of the Issue

1. To Meet Working Capital Requirements 2. Investment in Subsidiary 3. Upgradation / Construction of Existing /New Building in the Existing Premises 4. General Corporate Purpose 5. To meet Public Issue Expenses

Issue

Category Nos Bid Bid (x)
QIB 1500000 1500000 1x
NII 450000 1818000 4x
Retail 1050000 955500 0.9x
EMP 0 0 0x
Total 3000000 4800000 1.6x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Sotac Pharmaceutical Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 29 49 73 77 104 97
Other Income 0 0 0 0 0 4
Total Income 29 49 73 78 104 101
Total Expenditure 27 47 67 70 96 83
Operating Profit 2 2 6 8 9 18
Interest 0 1 1 2 2 3
Depreciation 1 3 1 2 3 4
Exceptional Income / Expenses 0 0 0 1 0 0
Profit Before Tax 0 -2 5 4 4 11
Provision for Tax 0 0 2 2 0 2
Profit After Tax 0 -2 3 2 4 9
Adjustments 0 0 0 1 1 -1
Profit After Adjustments 0 -2 3 3 4 8
Adjusted Earnings Per Share 0.1 -2.9 3.6 3.6 3.9 7.3

Sotac Pharmaceutical Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 3 2 7 19 45 53
Minority's Interest 2 0 0 0 4 5
Borrowings 6 9 1 8 12 14
Other Non-Current Liabilities 0 0 0 0 -1 -1
Total Current Liabilities 19 23 28 46 44 52
Total Liabilities 30 35 35 74 104 123
Fixed Assets 16 17 9 26 36 49
Other Non-Current Assets 1 1 1 1 8 5
Total Current Assets 14 17 26 47 61 70
Total Assets 30 35 35 74 104 123

Sotac Pharmaceutical Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 1 0 0 0 10 3
Cash Flow from Operating Activities 0 -0 6 8 -16 -4
Cash Flow from Investing Activities -12 -3 -4 -12 -20 -14
Cash Flow from Financing Activities 11 3 -3 13 29 16
Net Cash Inflow / Outflow -0 -0 0 10 -6 -2
Closing Cash & Cash Equivalent 0 0 0 10 3 2

Sotac Pharmaceutical Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.11 -2.94 3.58 3.58 3.87 7.26
CEPS(Rs) 1.85 0.28 4.98 5.67 6.05 11.86
DPS(Rs) 0 0 2 0 0 0.1
Book NAV/Share(Rs) 3.8 3.1 8.23 12.41 40.96 48.19
Core EBITDA Margin(%) 6.53 2.98 8.44 9.44 8.01 14.06
EBIT Margin(%) 2.41 -2.11 7.2 7.7 5.49 14.13
Pre Tax Margin(%) 1.25 -4.21 6.42 5.07 3.82 11.47
PAT Margin (%) 0.31 -4.84 3.94 2.95 3.45 9.56
Cash Profit Margin (%) 5.2 0.47 5.48 5.89 6.43 13.52
ROA(%) 0.29 -7.27 8.23 4.2 4.03 8.17
ROE(%) 2.86 -85.23 63.16 27.53 12.96 18.83
ROCE(%) 4.18 -5.71 31.31 21.5 10.22 16.4
Receivable days 88.82 47.99 45.25 63.58 72.11 113.65
Inventory Days 29.65 26.72 25.51 44.84 55.63 72.01
Payable days 193.78 112.91 106.65 143.83 124.45 127.81
PER(x) 0 0 0 0 31.23 16.35
Price/Book(x) 0 0 0 0 2.95 2.46
Dividend Yield(%) 0 0 0 0 0 0.08
EV/Net Sales(x) 0.54 0.39 0.13 0.26 1.49 1.79
EV/Core EBITDA(x) 7.33 12.26 1.51 2.66 17.63 9.89
Net Sales Growth(%) 0 70.76 49.77 5.92 34 -6.59
EBIT Growth(%) 0 -249.43 610.65 13.37 -4.46 140.28
PAT Growth(%) 0 -2803.31 221.7 -20.58 56.57 159.14
EPS Growth(%) 0 -2803.31 221.7 0.03 8.32 87.48
Debt/Equity(x) 4.4 6.87 1.12 2.21 0.55 0.82
Current Ratio(x) 0.71 0.76 0.94 1.03 1.39 1.35
Quick Ratio(x) 0.59 0.55 0.74 0.73 0.98 0.96
Interest Cover(x) 2.07 -1.01 9.24 2.92 3.28 5.31
Total Debt/Mcap(x) 0 0 0 0 0.19 0.33

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -7% 10% 27% 0%
Operating Profit CAGR 100% 44% 55% 0%
PAT CAGR 125% 44% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -12% -7% NA% NA%
ROE Average 19% 20% 7% 7%
ROCE Average 16% 16% 15% 13%

Company Contact Information

Sotac Pharmaceuticals Ltd.

Plot No. P F -21 & P F -22/ A Charal Industrial Estate Sanand G I D C - I I , Sanand

IPO Lead Manager(s)

Sotac Pharmaceuticals Ltd.

Beeline Capital Advisors Pvt Ltd.

Registrar Info

Sotac Pharmaceuticals Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!